A Altenburg1,2, M Augustin3, C C Zouboulis4. 1. Hochschulklinik für Dermatologie, Venerologie und Allergologie, Immunologisches Zentrum, Städtisches Klinikum Dessau, Medizinische Hochschule Brandenburg Theodor Fontane, Auenweg 38, 06847, Dessau-Roßlau, Deutschland. andreas.altenburg@klinikum-dessau.de. 2. MVZ des Städtischen Klinikums Dessau gGmbH, Luchstr. 19, 06862, Dessau-Roßlau, Deutschland. andreas.altenburg@klinikum-dessau.de. 3. Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen, CVderm, Universitätsklinikum Hamburg-Eppendorf (UKE), Martinistr. 52, 20246, Hamburg, Deutschland. 4. Hochschulklinik für Dermatologie, Venerologie und Allergologie, Immunologisches Zentrum, Städtisches Klinikum Dessau, Medizinische Hochschule Brandenburg Theodor Fontane, Auenweg 38, 06847, Dessau-Roßlau, Deutschland.
Abstract
BACKGROUND: The introduction of biologics has revolutionized the treatment of moderate to severe plaque psoriasis. Due to the continuous expansion of biological therapies for psoriasis, it is particularly important to acknowledge efficacy and safety of the compounds not only in clinical trials but also in long-term registry-based observational studies. AIM: Typical side effects and significant risks of antipsoriatic biologic therapies considering psoriatic control groups are presented. MATERIALS AND METHODS: A selective literature search was conducted in PubMed and long-term safety studies of the psoriasis registries PsoBest, PSOLAR and BADBIR were evaluated. RESULTS AND DISCUSSION: To assess the long-term safety of biologics, the evaluation of the course of large patient cohorts in long-term registries is of particular medical importance. Newer biologic drugs seem to exhibit a better safety profile than older ones.
BACKGROUND: The introduction of biologics has revolutionized the treatment of moderate to severe plaque psoriasis. Due to the continuous expansion of biological therapies for psoriasis, it is particularly important to acknowledge efficacy and safety of the compounds not only in clinical trials but also in long-term registry-based observational studies. AIM: Typical side effects and significant risks of antipsoriatic biologic therapies considering psoriatic control groups are presented. MATERIALS AND METHODS: A selective literature search was conducted in PubMed and long-term safety studies of the psoriasis registries PsoBest, PSOLAR and BADBIR were evaluated. RESULTS AND DISCUSSION: To assess the long-term safety of biologics, the evaluation of the course of large patient cohorts in long-term registries is of particular medical importance. Newer biologic drugs seem to exhibit a better safety profile than older ones.
Authors: Richard Hastings; Tina Ding; Sayqa Butt; Kate Gadsby; Weiya Zhang; Robert J Moots; Chris Deighton Journal: Arthritis Care Res (Hoboken) Date: 2010-06 Impact factor: 4.794
Authors: Mark Lebwohl; Craig Leonardi; Christopher E M Griffiths; Jörg C Prinz; Philippe O Szapary; Newman Yeilding; Cynthia Guzzo; Shu Li; Ming-Chun Hsu; Bruce Strober Journal: J Am Acad Dermatol Date: 2011-09-17 Impact factor: 11.527
Authors: Alan Menter; Steven R Feldman; Gerald D Weinstein; Kim Papp; Robert Evans; Cynthia Guzzo; Shu Li; Lisa T Dooley; Cynthia Arnold; Alice B Gottlieb Journal: J Am Acad Dermatol Date: 2006-09-06 Impact factor: 11.527
Authors: Alice B Gottlieb; Robert E Kalb; Richard G Langley; Gerald G Krueger; Elke M G J de Jong; Lynn Guenther; Kavitha Goyal; Steven Fakharzadeh; Marc Chevrier; Stephen Calabro; Wayne Langholff; Alan Menter Journal: J Drugs Dermatol Date: 2014-12 Impact factor: 2.114
Authors: Kim A Papp; Richard G Langley; Mark Lebwohl; Gerald G Krueger; Philippe Szapary; Newman Yeilding; Cynthia Guzzo; Ming-Chun Hsu; Yuhua Wang; Shu Li; Lisa T Dooley; Kristian Reich Journal: Lancet Date: 2008-05-17 Impact factor: 79.321
Authors: K Reich; U Mrowietz; M A Radtke; D Thaci; S J Rustenbach; C Spehr; M Augustin Journal: Arch Dermatol Res Date: 2015-09-10 Impact factor: 3.017